COMP <GO>
APYX vs UNH // REVENUE GROWTH (YOY)
Apyx Medical Corporation (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: APYX 1
— UNH 10
▲ REVENUE GROWTH (YOY) LEADER: APYX
LAST: $2.69 (+3.07%) • MKT CAP: $113.3M
revenue-growth
9.90%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APYX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APYX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.50% | 88.57% | -26.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.90% | 11.47% | -40.37 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.04% | 6.48% | -14.52 | UNH | /fcf-yield <GO> |
| Operating Margin | -12.20% | 4.82% | -17.02 | UNH | /operating-margins <GO> |
| Net Profit Margin | -21.20% | 3.14% | -24.34 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 9.90% | 6.46% | +3.44 | APYX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.75 | 3.12 | -2.37 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 59.2 | -10.05 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $113.3M | $368.83B | -$368.72B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APYX REV | UNH REV | APYX GROSS % | UNH GROSS % | APYX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $52.8M | $447.57B | 62.5% | 88.7% | -$9.1M | $16.07B |
| FY 2024 | $48.1M | $400.28B | 61.0% | 88.3% | -$18.8M | $20.70B |
| FY 2023 | $52.3M | $371.62B | — | 89.6% | -$5.2M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APYX // BETA —
UNH // BETA 0.33